It has been noticed that overexpression of eIF4B in DLBCL patients enhances the expression of several key proteins (DAXX, BCL2 and ERCC5), while reduced expression of eIF4B decreases the synthesis of those proteins and tumor cell survival, so the expression levels of eIF4B, ERCC5 and DAXX are directly correlated with the survival rate of patients (31). The gene discussed is EIF4B; the disease is diffuse large B-cell lymphoma.